Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00684177 · ClinicalTrials.gov registry record · Phase 3
Retapamulin Versus Placebo in Secondarily-Infected Traumatic Lesions (SITL)
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 508
- Enrollment target
NCT00684177 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 508 participants.
The verdict
NCT00684177, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 508 participants
- Enrollment target
Study Summary
The purpose of Study TOC110977 is to demonstrate clinical superiority of Retapamulin ointment, 1%, over placebo in patients with secondarily-infected traumatic lesions, which includes secondarily-infected lacerations, abrasions and sutured wounds. Subjects 2 months of age and older will be treated with topical retapamulin or placebo ointment twice daily for 5 days. The primary endpoint of this study is the clinical response at follow-up (Day 12-14; 7-9 days after the end of therapy) in the intent-to-treat clinical population.
Interventions
- DRUG Placebo ointment
- DRUG Retapamulin Ointment, 1%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 508 participants |
| Start Date | 2008-05 |
| Est. Completion | 2009-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00684177
The ClinicalTrials.gov registry entry for NCT00684177 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 508 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo ointment is the first listed.
NCT00684177 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00684177 about?
NCT00684177 is a clinical study titled "Retapamulin Versus Placebo in Secondarily-Infected Traumatic Lesions (SITL)". The purpose of Study TOC110977 is to demonstrate clinical superiority of Retapamulin ointment, 1%, over placebo in patients with secondarily-infected traumatic lesions, which includes secondarily-infected lacerations, abrasions and sutured wounds. Subjects 2 months of age and older will be treated w...
What is the current status of trial NCT00684177?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 508 participants. The study started on 2008-05. Estimated completion is 2009-10.
What interventions are being tested in trial NCT00684177?
The interventions under investigation include: Placebo ointment (DRUG), Retapamulin Ointment, 1% (DRUG).
Who is sponsoring clinical trial NCT00684177?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.